These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3816969)

  • 1. Phenethylamine hallucinogens in the locus coeruleus: potency of action correlates with rank order of 5-HT2 binding affinity.
    Rasmussen K; Glennon RA; Aghajanian GK
    Eur J Pharmacol; 1986 Dec; 132(1):79-82. PubMed ID: 3816969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity.
    Rasmussen K; Aghajanian GK
    Neuropsychopharmacology; 1988 May; 1(2):101-7. PubMed ID: 2908015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2 antagonists.
    Rasmussen K; Aghajanian GK
    Brain Res; 1986 Oct; 385(2):395-400. PubMed ID: 3096493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse.
    Glennon RA; Titeler M; Lyon RA
    Pharmacol Biochem Behav; 1988 Jul; 30(3):597-601. PubMed ID: 3211969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors.
    Titeler M; Herrick K; Lyon RA; McKenney JD; Glennon RA
    Eur J Pharmacol; 1985 Oct; 117(1):145-6. PubMed ID: 4085543
    [No Abstract]   [Full Text] [Related]  

  • 6. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens.
    Titeler M; Lyon RA; Glennon RA
    Psychopharmacology (Berl); 1988; 94(2):213-6. PubMed ID: 3127847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent agonist activity of DOB at 5-HT2 receptors in guinea pig trachea.
    Heller WA; Baraban JM
    Eur J Pharmacol; 1987 Jun; 138(1):115-7. PubMed ID: 3622603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin2 agonist administration down-regulates rat brain serotonin2 receptors.
    Buckholtz NS; Zhou DF; Freedman DX
    Life Sci; 1988; 42(24):2439-45. PubMed ID: 3374263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonergic regulation of noradrenergic coerulean neurons: electrophysiological evidence for the involvement of 5-HT2 receptors.
    Gorea E; Adrien J
    Eur J Pharmacol; 1988 Sep; 154(3):285-91. PubMed ID: 3234483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of 5-hydroxytryptamine2 receptor-mediated phosphatidylinositol turnover by d-lysergic acid diethylamide.
    Pierce PA; Peroutka SJ
    J Pharmacol Exp Ther; 1988 Dec; 247(3):918-25. PubMed ID: 3204523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible involvement of serotonin receptors in the facilitatory effect of a hallucinogenic phenethylamine on single facial motoneurons.
    Penington NJ; Reiffenstein RJ
    Can J Physiol Pharmacol; 1986 Oct; 64(10):1302-9. PubMed ID: 3801984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (R)-(-)-[77Br]4-bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes.
    Peroutka SJ; Hamik A; Harrington MA; Hoffman AJ; Mathis CA; Pierce PA; Wang SS
    Mol Pharmacol; 1988 Oct; 34(4):537-42. PubMed ID: 3173334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinogenic drugs.
    Sanders-Bush E; Breeding M
    Psychopharmacology (Berl); 1991; 105(3):340-6. PubMed ID: 1665919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex.
    Pierce PA; Peroutka SJ
    Psychopharmacology (Berl); 1989; 97(1):118-22. PubMed ID: 2540505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis.
    Sanders-Bush E; Burris KD; Knoth K
    J Pharmacol Exp Ther; 1988 Sep; 246(3):924-8. PubMed ID: 2843634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid desensitization and down-regulation of 5-HT2 receptors by DOM treatment.
    Leysen JE; Janssen PF; Niemegeers CJ
    Eur J Pharmacol; 1989 Apr; 163(1):145-9. PubMed ID: 2545460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. II. Biochemical and physiological evidence for the development of tolerance after chronic administration.
    Owens MJ; Knight DL; Ritchie JC; Nemeroff CB
    J Pharmacol Exp Ther; 1991 Feb; 256(2):795-800. PubMed ID: 1847213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors.
    Lyon RA; Davis KH; Titeler M
    Mol Pharmacol; 1987 Feb; 31(2):194-9. PubMed ID: 3543649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that 5-HT2 receptor activation decreases noradrenaline release in rat hippocampus in vivo.
    Done CJ; Sharp T
    Br J Pharmacol; 1992 Sep; 107(1):240-5. PubMed ID: 1422575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R(-)-2,5-dimethoxy-4-77 bromoamphetamine [77Br-R(-)DOB]: a novel radioligand which labels a 5-HT binding site subtype.
    Wang SS; Mathis CA; Peroutka SJ
    Psychopharmacology (Berl); 1988; 94(3):431-2. PubMed ID: 3357926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.